Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/27919
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWeerawat Manosuthien_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.authorPreecha Tantanathipen_US
dc.contributor.authorWiroj Mankatithamen_US
dc.contributor.authorAroon Lueangniyomkulen_US
dc.contributor.authorSupeda Thongyenen_US
dc.contributor.authorBoonchuay Eampokarapen_US
dc.contributor.authorSumonmal Uttayamakulen_US
dc.contributor.authorPawita Suwanvattanaen_US
dc.contributor.authorSamroui Kaewsaarden_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherBamrasnaradura Infectious Diseases Instituteen_US
dc.date.accessioned2018-09-13T06:53:54Z-
dc.date.available2018-09-13T06:53:54Z-
dc.date.issued2009-10-01en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.53, No.10 (2009), 4545-4548en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-70349313476en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70349313476&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/27919-
dc.description.abstractSeventy-one human immunodeficiency virus-infected patients with tuberculosis who were receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C12) were monitored. The mean ± standard deviation efavirenz C12 at weeks 6 and 12 and after rifampin discontinuation were 4.5 ± 4.3, 3.8 ± 3.5, and 3.5 ± 2.7 mg/liter, respectively. High body weight was associated with a low efavirenz C12 at weeks 6 and 12 (P = 0.003, r = -0.255). The efavirenz C12 regression prediction line at 1 mg/liter intercepted a mean body weight of 57.5 kg. Copyright © 2009, American Society for Microbiology. All Rights Reserved.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70349313476&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleBody weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampinen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1128/AAC.00492-09en_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.